Literature DB >> 27402613

Metabolic history impacts mammary tumor epithelial hierarchy and early drug response in mice.

Maria Theresa E Montales1, Stepan B Melnyk2, Shi J Liu3, Frank A Simmen4, Y Lucy Liu5, Rosalia C M Simmen6.   

Abstract

The emerging links between breast cancer and metabolic dysfunctions brought forth by the obesity pandemic predict a disproportionate early disease onset in successive generations. Moreover, sensitivity to chemotherapeutic agents may be influenced by the patient's metabolic status that affects the disease outcome. Maternal metabolic stress as a determinant of drug response in progeny is not well defined. Here, we evaluated mammary tumor response to doxorubicin in female mouse mammary tumor virus-Wnt1 transgenic offspring exposed to a metabolically compromised environment imposed by maternal high-fat diet. Control progeny were from dams consuming diets with regular fat content. Maternal high-fat diet exposure increased tumor incidence and reduced tumor latency but did not affect tumor volume response to doxorubicin, compared with control diet exposure. However, doxorubicin-treated tumors from high-fat-diet-exposed offspring demonstrated higher proliferation status (Ki-67), mammary stem cell-associated gene expression (Notch1, Aldh1) and basal stem cell-like (CD29(hi)CD24(+)) epithelial subpopulation frequencies, than tumors from control diet progeny. Notably, all epithelial subpopulations (CD29(hi)CD24(+), CD29(lo)CD24(+), CD29(hi)CD24(+)Thy1(+)) in tumors from high-fat-diet-exposed offspring were refractory to doxorubicin. Further, sera from high-fat-diet-exposed offspring promoted sphere formation of mouse mammary tumor epithelial cells and of human MCF7 cells. Untargeted metabolomics analyses identified higher levels of kynurenine and 2-hydroxyglutarate in plasma of high-fat diet than control diet offspring. Kynurenine/doxorubicin co-treatment of MCF7 cells enhanced the ability to form mammosphere and decreased apoptosis, relative to doxorubicin-only-treated cells. Maternal metabolic dysfunctions during pregnancy and lactation may be targeted to reduce breast cancer risk and improve early drug response in progeny, and may inform clinical management of disease.
© 2016 Society for Endocrinology.

Entities:  

Keywords:  breast cancer; doxorubicin; high-fat diet; kynurenine metabolite; stem cells

Mesh:

Substances:

Year:  2016        PMID: 27402613      PMCID: PMC4997088          DOI: 10.1530/ERC-16-0136

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  57 in total

Review 1.  Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis.

Authors:  Jane E Visvader
Journal:  Genes Dev       Date:  2009-11-15       Impact factor: 11.361

Review 2.  Metabolic syndrome and breast cancer: is there a link?

Authors:  Dagmar Hauner; Hans Hauner
Journal:  Breast Care (Basel)       Date:  2014-04       Impact factor: 2.860

Review 3.  How many etiological subtypes of breast cancer: two, three, four, or more?

Authors:  William F Anderson; Philip S Rosenberg; Aleix Prat; Charles M Perou; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2014-08-12       Impact factor: 13.506

Review 4.  Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer.

Authors:  Y Li; W P Hively; H E Varmus
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

5.  A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection.

Authors:  S Melnyk; M Pogribna; I Pogribny; R J Hine; S J James
Journal:  J Nutr Biochem       Date:  1999-08       Impact factor: 6.048

6.  Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner.

Authors:  Weiwei Tao; Jun-Feng Shi; Qian Zhang; Bin Xue; Yu-Jie Sun; Chao-Jun Li
Journal:  Biomed Pharmacother       Date:  2013-02-01       Impact factor: 6.529

7.  Maternal metabolic perturbations elicited by high-fat diet promote Wnt-1-induced mammary tumor risk in adult female offspring via long-term effects on mammary and systemic phenotypes.

Authors:  Maria Theresa E Montales; Stepan B Melnyk; Frank A Simmen; Rosalia C M Simmen
Journal:  Carcinogenesis       Date:  2014-05-15       Impact factor: 4.944

8.  The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer.

Authors:  C Parr; G Watkins; W G Jiang
Journal:  Int J Mol Med       Date:  2004-11       Impact factor: 4.101

9.  Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer.

Authors:  Dongping Li; Yaroslav Ilnytskyy; Anna Kovalchuk; Levon M Khachigian; Roderick T Bronson; Bo Wang; Olga Kovalchuk
Journal:  Oncotarget       Date:  2013-09

10.  Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.

Authors:  Edmund Chinchar; Kristina L Makey; John Gibson; Fang Chen; Shelby A Cole; Gail C Megason; Srinivassan Vijayakumar; Lucio Miele; Jian-Wei Gu
Journal:  Vasc Cell       Date:  2014-06-01
View more
  4 in total

1.  Maternal obesity increases offspring's mammary cancer recurrence and impairs tumor immune response.

Authors:  Xiyuan Zhang; Fabia de Oliveira Andrade; Hansheng Zhang; Idalia Cruz; Robert Clarke; Pankaj Gaur; Vivek Verma; Leena Hilakivi-Clarke
Journal:  Endocr Relat Cancer       Date:  2020-09       Impact factor: 5.678

Review 2.  Metabolomics and health: from nutritional crops and plant-based pharmaceuticals to profiling of human biofluids.

Authors:  Andrey S Marchev; Liliya V Vasileva; Kristiana M Amirova; Martina S Savova; Zhivka P Balcheva-Sivenova; Milen I Georgiev
Journal:  Cell Mol Life Sci       Date:  2021-08-19       Impact factor: 9.261

3.  Integrated bioinformatical analysis, machine learning and in vitro experiment-identified m6A subtype, and predictive drug target signatures for diagnosing renal fibrosis.

Authors:  Chunxiang Feng; Zhixian Wang; Chang Liu; Shiliang Liu; Yuxi Wang; Yuanyuan Zeng; Qianqian Wang; Tianming Peng; Xiaoyong Pu; Jiumin Liu
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

4.  Leptin signaling and cancer chemoresistance: Perspectives.

Authors:  Pierre V Candelaria; Antonio Rampoldi; Adriana Harbuzariu; Ruben R Gonzalez-Perez
Journal:  World J Clin Oncol       Date:  2017-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.